Loading...


The current price of HIND is 4.1 USD — it has decreased -11.26 % in the last trading day.
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Wall Street analysts forecast HIND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIND is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Vyome Holdings Inc revenue for the last quarter amounts to 34.63K USD, decreased -98.49 % YoY.
Vyome Holdings Inc. EPS for the last quarter amounts to -3.06 USD, decreased -99.02 % YoY.
Vyome Holdings Inc (HIND) has 17 emplpoyees as of December 16 2025.
Today HIND has the market capitalization of 23.14M USD.